2 months Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom Investor's Business Daily
Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug.
The post Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom appeared first on Investor's Business D…